

Brian Bressler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9450934/publications.pdf>

Version: 2024-02-01

79
papers

2,494
citations

304743

22
h-index

206112

48
g-index

81
all docs

81
docs citations

81
times ranked

3910
citing authors

#	ARTICLE	IF	CITATIONS
1	Ustekinumab Therapeutic Drug Monitoringâ€™ Impact on Clinical Practice: A Multicenter Cross-Sectional Observational Trial. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3148-3157.	2.3	4
2	Cost-Effectiveness of Tight Control for Crohnâ€™s Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 169-176.	0.3	5
3	Time to Revisit Disease Classification in Inflammatory Bowel Disease: Is the Current Classification of Inflammatory Bowel Disease Good Enough for Optimal Clinical Management?. <i>Gastroenterology</i> , 2022, 162, 1370-1382.	1.3	26
4	Has the Time Come to Say Goodbye to Therapeutic Drug Monitoring As We Know It?. <i>Gastroenterology</i> , 2022, , .	1.3	5
5	Impact of Telehealth on Medication Adherence in Chronic Gastrointestinal Diseases. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 203-207.	0.3	3
6	Vedolizumab and Anti-Tumour Necrosis Factor Î± Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1694-1706.	1.3	62
7	Interleukin-37 regulates innate immune signaling in human and mouse colonic organoids. <i>Scientific Reports</i> , 2021, 11, 8206.	3.3	15
8	Clinician perspectives on the use of artificial intelligence in inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 662-663.	1.0	2
9	International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1942-1953.	1.9	30
10	Update on the Use of Vedolizumab in Patients With Crohn's Disease.. <i>Gastroenterology and Hepatology</i> , 2021, 17, 491-493.	0.1	0
11	Acute Severe Ulcerative Colitis: The Oxford Criteria No Longer Predict In-Hospital Colectomy Rates. <i>Digestive Diseases and Sciences</i> , 2020, 65, 576-580.	2.3	18
12	Validation of the St. Paulâ€™s Endoscopy Comfort Scale (SPECS) for Colonoscopy. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 91-95.	0.3	10
13	Development of a Global Rating Scale for Inflammatory Bowel Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 4-16.	0.3	2
14	Do You See What I See? An Assessment of Endoscopic Lesions Recognition and Description by Gastroenterology Trainees and Staff Physicians. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 216-221.	0.3	3
15	Enteroids Derived From Inflammatory Bowel Disease Patients Display Dysregulated Endoplasmic Reticulum Stress Pathways, Leading to Differential Inflammatory Responses and Dendritic Cell Maturation. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 948-961.	1.3	30
16	Analysis of Flagellin-Specific Adaptive Immunity Reveals Links to Dysbiosis in Patients With Inflammatory Bowel Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 9, 485-506.	4.5	22
17	Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 997-998.	3.7	2
18	Pharmacological inhibition of RORC2 enhances human Th17â€™reg stability and function. <i>European Journal of Immunology</i> , 2020, 50, 1400-1411.	2.9	14

#	ARTICLE	IF	CITATIONS
19	Providing Hospitalized Ulcerative Colitis Patients With Practice Guidelines Improves Patient-Reported Outcomes. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 4, 131-136.	0.3	4
20	Clinical Implications of Recent Findings From the EVOLVE Study. <i>Gastroenterology and Hepatology</i> , 2020, 16, 420-422.	0.1	0
21	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1-13.	1.9	73
22	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1680-1713.	4.4	32
23	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, e1-e34.	0.3	32
24	Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 149-152.	0.3	5
25	Internet-Based Patient Education Prior to Colonoscopy: Prospective, Observational Study of a Single Center's Implementation, with Objective Assessment of Bowel Preparation Quality and Patient Satisfaction. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 3, 274-278.	0.3	0
26	Editorial: aminosalicylates and nephrotoxicity—an issue put to rest. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1059-1059.	3.7	0
27	Suppressive and Gut-Reparative Functions of Human Type 1 T Regulatory Cells. <i>Gastroenterology</i> , 2019, 157, 1584-1598.	1.3	81
28	Healthcare Providers Underestimate Patients' Glucocorticoid Use in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1142-1149.	2.3	5
29	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. <i>Journal of Rheumatology</i> , 2019, 46, 751-754.	2.0	22
30	Patterns and motivations of Cannabis use amongst patients with inflammatory bowel disease. <i>GastroHep</i> , 2019, 1, 100-107.	0.6	8
31	Innate Control of Tissue-Reparative Human Regulatory T Cells. <i>Journal of Immunology</i> , 2019, 202, 2195-2209.	0.8	35
32	An automated mass spectrometric blood test for therapeutic drug monitoring of infliximab. <i>Clinical Mass Spectrometry</i> , 2019, 12, 16-22.	1.9	7
33	Selection of Quality Indicators in IBD: Integrating Physician and Patient Perspectives. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 403-409.	1.9	25
34	IBDoc Canadian User Performance Evaluation. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1107-1114.	1.9	8
35	Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 50-74.	1.2	87
36	Use of Vedolizumab for the Treatment of Crohn's Disease. <i>Gastroenterology and Hepatology</i> , 2019, 15, 204-206.	0.1	2

#	ARTICLE	IF	CITATIONS
37	Prospective Comparison of Standard- Versus Low-Radiation-Dose CT Enterography for the Quantitative Assessment of Crohn Disease. <i>American Journal of Roentgenology</i> , 2018, 210, W54-W62.	2.2	18
38	Frontline defenders: goblet cell mediators dictate host-microbe interactions in the intestinal tract during health and disease. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G360-G377.	3.4	49
39	Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis. <i>Frontiers in Immunology</i> , 2018, 9, 2211.	4.8	22
40	Rate of Corticosteroid-Induced Mood Changes in Patients with Inflammatory Bowel Disease: A Prospective Study. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 99-106.	0.3	20
41	Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 129-134.	0.3	9
42	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 141-154.	0.3	10
43	Incidence of Suicide in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 107-114.	0.3	18
44	Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 858-865.	1.9	25
45	Biologic Therapy in Moderate-to-Severe Ulcerative Colitis: Infliximab. , 2017, , 429-433.		1
46	Ustekinumab use in Crohn's disease: a Canadian tertiary care centre experience. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1354-1359.	1.5	44
47	Prevalence of Anxiety and Depression in Patients with Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-6.	1.9	158
48	Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-11.	1.9	22
49	Transition clinic attendance is associated with improved beliefs and attitudes toward medicine in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2017, 23, 5405.	3.3	22
50	The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-7.	1.9	12
51	The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 330-338.	3.2	15
52	The Impact of Dietary Interventions on the Symptoms of Inflammatory Bowel Disease: A Systematic Review. <i>Critical Reviews in Food Science and Nutrition</i> , 2016, 56, 1370-1378.	10.3	51
53	Vedolizumab for the treatment of ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 129-135.	3.1	1
54	The Crohn's Disease's "Ulcerative Colitis Clinical Appraisal. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 638-639.	4.4	1

#	ARTICLE	IF	CITATIONS
55	The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. <i>Gastroenterology</i> , 2016, 150, 734-757.e1.	1.3	373
56	FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2016, 22, 8211.	3.3	10
57	Author response. <i>Canadian Journal of Surgery</i> , 2016, 59, E1.2-E2.	1.2	0
58	Cliniciansâ€™ Guide to the Use of Fecal Calprotectin to Identify and Monitor Disease Activity in Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 369-372.	1.9	58
59	Tacrolimus Therapy for Ulcerative Colitis-Associated Post-Colectomy Enteritis. <i>ACG Case Reports Journal</i> , 2015, 2, 33-35.	0.4	14
60	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. <i>Gastroenterology</i> , 2015, 148, 1035-1058.e3.	1.3	323
61	Vedolizumab for induction and maintenance of remission in Crohnâ€™s disease. <i>The Cochrane Library</i> , 2015, , .	2.8	0
62	Colonoscopy after CT-diagnosed acute diverticulitis: Is it really necessary?. <i>Canadian Journal of Surgery</i> , 2015, 58, 226-231.	1.2	24
63	Canadian Association of Gastroenterology Position Statement Regarding the Use of Thiopurines for the Treatment of Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 371-372.	1.9	10
64	2 L versus 4 L of PEG3350 + electrolytes for outpatient colonic preparation: a randomized, controlled trial. <i>Gastrointestinal Endoscopy</i> , 2014, 79, 408-416.e4.	1.0	37
65	Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology. <i>Gastroenterology</i> , 2014, 146, 835-848.e6.	1.3	277
66	Effective Tuberculosis and Hepatitis Screening Prior to Anti-TNF-Î± Therapy: Are We There Yet?. <i>Digestive Diseases and Sciences</i> , 2014, 59, 507-509.	2.3	3
67	A randomized controlled trial assessing the effect of prescribed patient position changes during colonoscopy withdrawal on adenoma detection. <i>Gastrointestinal Endoscopy</i> , 2014, 80, 277-283.e1.	1.0	41
68	Time of infliximab therapy initiation and dose escalation in Crohnâ€™s disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 214.	3.3	7
69	Impact of medical therapy on patients with Crohnâ€™s disease requiring surgical resection. <i>World Journal of Gastroenterology</i> , 2014, 20, 11808.	3.3	7
70	Does training and experience influence the accuracy of computed tomography colonography interpretation?. <i>World Journal of Gastroenterology</i> , 2014, 20, 1574.	3.3	1
71	Performance of interferon-gamma release assays in patients with inflammatory bowel disease: A systematic review and meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2034-2042.	1.9	60
72	Optimizing Use of Tumor Necrosis Factor Inhibitors in the Management of Immune-Mediated Inflammatory Diseases. <i>Journal of rheumatology Supplement, The</i> , 2010, 85, 40-52.	2.2	15

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN α (40KD) (PEGASYS [®]). <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 280-287.	2.4	14
74	How to manage difficult Crohn's disease: optimum delivery of anti-TNFs. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 407-415.	3.0	4
75	Mild to Moderate Crohn's Disease. <i>Drugs</i> , 2008, 68, 2419-2425.	10.9	8
76	Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007, 1, 29-39.	3.0	8
77	Adalimumab in Crohn's Disease. <i>BioDrugs</i> , 2007, 21, 133-134.	4.6	1
78	The Role of Endoscopy in the Management of Postoperative Patients with Crohn's Disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2006, 20, 631-632.	1.7	0
79	Prospective evaluation of screening colonoscopy: who is being screened?. <i>Gastrointestinal Endoscopy</i> , 2004, 60, 921-926.	1.0	22